REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Clinical trials for REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…
Matched conditions: REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:37 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…
Matched conditions: REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New combo therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…
Matched conditions: REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 18, 2026 12:09 UTC